{"ticker": {"uuid": "830c2031-286f-426e-9635-9055d5c89ea5", "symbol": "NTGY", "name": "Naturgy Energy Group, S.A.", "exchange": "MCE", "country": "ES", "sector": "Utilities", "industry": "Utilities - Regulated Gas"}, "articles": [{"title": "Nextensa delivers strong half-year results, supported by several successful transactions", "summary": "Nextensa NV PRESS RELEASE Regulated information Brussels, 12 August 2026, 5:55PM HIGHLIGHTS Nextensadeliversstronghalf-yearresults,supportedbyseveralsuccessful transactions Nextensa achieved strong results in the first half of 2026. The period was marked by several successful transactions, including the sale of Gewerbepark Stadlau in Vienna, the forward sale of The Rock and the sale of B&B Hotels in Cloche d'Or. The granting of the planning and environmental permits for Lake Side in Brussels and the reservation by Vicinity of a substantial residential portion of Bel Towers further underline th", "url": "https://finance.yahoo.com/real-estate/articles/nextensa-delivers-strong-half-results-155500459.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:55:00+00:00", "published_display": "12 Aug 2026 15:55", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.237, "duplicate_count": 1, "topics": ["Balance Sheet", "Development", "Dividends", "Financials", "Real Estate", "Transactions"]}, {"title": "Pierre & Vacances-Center Parcs: Total Number of Shares and Voting Rights", "summary": "Pursuant to Article L. 233-8 of the French Commercial Code and Article 223-16 of the General Regulations of the French Autorit\u00e9 des march\u00e9s financiers PARIS, August 12, 2026--(BUSINESS WIRE)--Regulatory News: Pierre & Vacances-Center Parcs (Paris:VAC): Date Number of shares(*) Number of theoretical voting rights Number of actual voting rights (exercisable at General Meetings) (**) 31 July 2026 462 008 714 462 008 714 461 904 805 (*) Ordinary shares only, i.e. excluding 1,130 preferred shares not admitted to trading. (**) Excluding treasury shares, which are deprived of voting rights (the 1,130", "url": "https://finance.yahoo.com/markets/stocks/articles/pierre-vacances-center-parcs-total-133700984.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T13:37:00+00:00", "published_display": "12 Aug 2026 13:37", "sentiment": "positive", "sentiment_pct": 59, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.267, "duplicate_count": 1, "topics": ["Regulation"]}, {"title": "technotrans SE (WBO:TTR1) (Q2 2026) Earnings Call Highlights: Margin Resilience and Strategic ...", "summary": "This article first appeared on GuruFocus. Revenue: EUR113.3 million in H1 2026, down 6% from EUR120.6 million in the prior year. EBIT: EUR8.0 million in H1 2026, compared to EUR8.4 million one year ago. EBIT Margin: Increased to 7.1% from 7.0% in the prior year. Gross Profit: EUR34.2 million, with gross margin improving to 30.2% from 29.8%. EBITDA: EUR11.2 million, compared to EUR11.9 million in the previous year; EBITDA margin rose to 9.9% from 9.8%. Net Profit: EUR4.9 million, down from EUR5.2 million in the prior year. Earnings Per Share: EUR0.71, compared to EUR0.75 in the previous year. F", "url": "https://finance.yahoo.com/markets/stocks/articles/technotrans-se-wbo-ttr1-q2-010228002.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T01:02:28+00:00", "published_display": "12 Aug 2026 01:02", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.269, "duplicate_count": 1, "topics": ["Earnings", "Growth Rate", "Guidance", "Plastics", "Revenue", "Supply Chain"]}, {"title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "summary": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investmen", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:30:00+00:00", "published_display": "11 Aug 2026 14:30", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.195, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Oncology", "Quarterly Results"]}, {"title": "Rational AG (RATIY) (Q2 2026) Earnings Call Highlights: Record EBIT Margin and Strategic ...", "summary": "This article first appeared on GuruFocus. Revenue (H1 2026): EUR642 million, up 8% organically and 6% after FX adjustments. Revenue (Q2 2026): EUR324 million, up 4% year-over-year. EBIT (H1 2026): EUR170 million, up 11% year-over-year, with a margin of 26.5% (24.3% excluding tariff refunds). Gross Margin (H1 2026): Improved to 59.8%. Operating Expenses (H1 2026): Increased 5% year-over-year to EUR250 million. iCombi Revenue (H1 2026): EUR562 million, up 5%. iVario Revenue (H1 2026): EUR79 million, up 14%, with North America growing 24%. Germany Revenue (H1 2026): Up 9%. Europe (ex-Germany) Rev", "url": "https://finance.yahoo.com/markets/stocks/articles/rational-ag-ratiy-q2-2026-010402063.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T01:04:02+00:00", "published_display": "11 Aug 2026 01:04", "sentiment": "positive", "sentiment_pct": 78, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.256, "duplicate_count": 1, "topics": ["Earnings", "EBIT Margin", "Growth Rate", "Guidance", "Revenue Growth", "Revenue Growth"]}, {"title": "CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong", "summary": "Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due to higher SG&A expenses tied to costs associated with the commercial launch of Myqorzo and lower revenues. Revenues amounted to $28.6 million, which went down from $66.8 million in the year-ago quarter but surpassed the Zacks Consensus Estimate of $20 million. Cytokinetics' shares have surged 28.1% year to date compared with the ind", "url": "https://finance.yahoo.com/healthcare/articles/cytk-q2-earnings-top-estimates-182200106.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T18:22:00+00:00", "published_display": "07 Aug 2026 18:22", "sentiment": "neutral", "sentiment_pct": 48, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.061, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Fourth Quarter", "Pharma"]}, {"title": "Bittium Oyj (HLSE:BITTI) Earnings Reset The Valuation Debate", "summary": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. How Bittium Oyj's Latest Earnings Shape the Investment Picture Bittium Oyj (HLSE:BITTI) reported half year 2026 sales of \u20ac57.9 million and net income of \u20ac7.5 million, compared with \u20ac42.3 million and \u20ac1.5 million a year earlier, which sharpened investor focus on the stock. Those figures, together with basic earnings per share from continuing operations of \u20ac0.211 compared with \u20ac0.043 a year ago, provide fresh data to reassess ", "url": "https://finance.yahoo.com/markets/stocks/articles/bittium-oyj-hlse-bitti-earnings-181044517.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T18:10:44+00:00", "published_display": "07 Aug 2026 18:10", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.1, "duplicate_count": 1, "topics": ["Balance Sheet", "Defense", "Earnings", "Earnings Growth", "Earnings Per Share", "Net Income"]}], "by_tier": {"direct": [{"title": "Nextensa delivers strong half-year results, supported by several successful transactions", "summary": "Nextensa NV PRESS RELEASE Regulated information Brussels, 12 August 2026, 5:55PM HIGHLIGHTS Nextensadeliversstronghalf-yearresults,supportedbyseveralsuccessful transactions Nextensa achieved strong results in the first half of 2026. The period was marked by several successful transactions, including the sale of Gewerbepark Stadlau in Vienna, the forward sale of The Rock and the sale of B&B Hotels in Cloche d'Or. The granting of the planning and environmental permits for Lake Side in Brussels and the reservation by Vicinity of a substantial residential portion of Bel Towers further underline th", "url": "https://finance.yahoo.com/real-estate/articles/nextensa-delivers-strong-half-results-155500459.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:55:00+00:00", "published_display": "12 Aug 2026 15:55", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.237, "duplicate_count": 1, "topics": ["Balance Sheet", "Development", "Dividends", "Financials", "Real Estate", "Transactions"]}, {"title": "Pierre & Vacances-Center Parcs: Total Number of Shares and Voting Rights", "summary": "Pursuant to Article L. 233-8 of the French Commercial Code and Article 223-16 of the General Regulations of the French Autorit\u00e9 des march\u00e9s financiers PARIS, August 12, 2026--(BUSINESS WIRE)--Regulatory News: Pierre & Vacances-Center Parcs (Paris:VAC): Date Number of shares(*) Number of theoretical voting rights Number of actual voting rights (exercisable at General Meetings) (**) 31 July 2026 462 008 714 462 008 714 461 904 805 (*) Ordinary shares only, i.e. excluding 1,130 preferred shares not admitted to trading. (**) Excluding treasury shares, which are deprived of voting rights (the 1,130", "url": "https://finance.yahoo.com/markets/stocks/articles/pierre-vacances-center-parcs-total-133700984.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T13:37:00+00:00", "published_display": "12 Aug 2026 13:37", "sentiment": "positive", "sentiment_pct": 59, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.267, "duplicate_count": 1, "topics": ["Regulation"]}, {"title": "technotrans SE (WBO:TTR1) (Q2 2026) Earnings Call Highlights: Margin Resilience and Strategic ...", "summary": "This article first appeared on GuruFocus. Revenue: EUR113.3 million in H1 2026, down 6% from EUR120.6 million in the prior year. EBIT: EUR8.0 million in H1 2026, compared to EUR8.4 million one year ago. EBIT Margin: Increased to 7.1% from 7.0% in the prior year. Gross Profit: EUR34.2 million, with gross margin improving to 30.2% from 29.8%. EBITDA: EUR11.2 million, compared to EUR11.9 million in the previous year; EBITDA margin rose to 9.9% from 9.8%. Net Profit: EUR4.9 million, down from EUR5.2 million in the prior year. Earnings Per Share: EUR0.71, compared to EUR0.75 in the previous year. F", "url": "https://finance.yahoo.com/markets/stocks/articles/technotrans-se-wbo-ttr1-q2-010228002.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T01:02:28+00:00", "published_display": "12 Aug 2026 01:02", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.269, "duplicate_count": 1, "topics": ["Earnings", "Growth Rate", "Guidance", "Plastics", "Revenue", "Supply Chain"]}, {"title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "summary": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investmen", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:30:00+00:00", "published_display": "11 Aug 2026 14:30", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.195, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Oncology", "Quarterly Results"]}, {"title": "Rational AG (RATIY) (Q2 2026) Earnings Call Highlights: Record EBIT Margin and Strategic ...", "summary": "This article first appeared on GuruFocus. Revenue (H1 2026): EUR642 million, up 8% organically and 6% after FX adjustments. Revenue (Q2 2026): EUR324 million, up 4% year-over-year. EBIT (H1 2026): EUR170 million, up 11% year-over-year, with a margin of 26.5% (24.3% excluding tariff refunds). Gross Margin (H1 2026): Improved to 59.8%. Operating Expenses (H1 2026): Increased 5% year-over-year to EUR250 million. iCombi Revenue (H1 2026): EUR562 million, up 5%. iVario Revenue (H1 2026): EUR79 million, up 14%, with North America growing 24%. Germany Revenue (H1 2026): Up 9%. Europe (ex-Germany) Rev", "url": "https://finance.yahoo.com/markets/stocks/articles/rational-ag-ratiy-q2-2026-010402063.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T01:04:02+00:00", "published_display": "11 Aug 2026 01:04", "sentiment": "positive", "sentiment_pct": 78, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.256, "duplicate_count": 1, "topics": ["Earnings", "EBIT Margin", "Growth Rate", "Guidance", "Revenue Growth", "Revenue Growth"]}, {"title": "CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong", "summary": "Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due to higher SG&A expenses tied to costs associated with the commercial launch of Myqorzo and lower revenues. Revenues amounted to $28.6 million, which went down from $66.8 million in the year-ago quarter but surpassed the Zacks Consensus Estimate of $20 million. Cytokinetics' shares have surged 28.1% year to date compared with the ind", "url": "https://finance.yahoo.com/healthcare/articles/cytk-q2-earnings-top-estimates-182200106.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T18:22:00+00:00", "published_display": "07 Aug 2026 18:22", "sentiment": "neutral", "sentiment_pct": 48, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.061, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Fourth Quarter", "Pharma"]}, {"title": "Bittium Oyj (HLSE:BITTI) Earnings Reset The Valuation Debate", "summary": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. How Bittium Oyj's Latest Earnings Shape the Investment Picture Bittium Oyj (HLSE:BITTI) reported half year 2026 sales of \u20ac57.9 million and net income of \u20ac7.5 million, compared with \u20ac42.3 million and \u20ac1.5 million a year earlier, which sharpened investor focus on the stock. Those figures, together with basic earnings per share from continuing operations of \u20ac0.211 compared with \u20ac0.043 a year ago, provide fresh data to reassess ", "url": "https://finance.yahoo.com/markets/stocks/articles/bittium-oyj-hlse-bitti-earnings-181044517.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T18:10:44+00:00", "published_display": "07 Aug 2026 18:10", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.1, "duplicate_count": 1, "topics": ["Balance Sheet", "Defense", "Earnings", "Earnings Growth", "Earnings Per Share", "Net Income"]}], "industry": [], "sector": []}, "total_fetched": 7, "total_unique": 7, "total_relevant": 7, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 7, "unique_stories": 7, "duplicates_removed": 0, "relevant_stories": 7, "current_evidence": 7, "direct_evidence": 7, "eodhd_articles": 7, "eodhd": {"configured": true, "status": "error", "calls_used": 75, "call_budget": 500, "budget_used_pct": 15.0, "requests_made": 15, "last_success_at": "2026-08-13T01:31:44.102323+00:00", "newest_seen_at": "2026-08-13T01:15:36+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "EODHD news request failed: ReadTimeout", "mapped_mentions": 3749, "unmapped_mentions": 1776}, "status": "healthy"}, "sentiment_summary": {"positive": 5, "negative": 1, "neutral": 1, "score": 61, "raw_score": 66, "total": 7, "evidence_count": 7, "effective_articles": 6.05, "direct_story_count": 7, "industry_story_count": 0, "sector_story_count": 0, "story_count": 7, "source_count": 1, "source_concentration": 1.0, "direct_share": 100, "dispersion": 16, "confidence": 71, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T15:55:00+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 82, "events": [{"event": "earnings", "label": "Earnings", "weight": 3.6, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.6, "count": 1}], "positive_events": 5, "negative_events": 1, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 7, "unique_stories": 7, "duplicates_removed": 0, "relevant_stories": 7, "current_evidence": 7, "direct_evidence": 7, "eodhd_articles": 7, "eodhd": {"configured": true, "status": "error", "calls_used": 75, "call_budget": 500, "budget_used_pct": 15.0, "requests_made": 15, "last_success_at": "2026-08-13T01:31:44.102323+00:00", "newest_seen_at": "2026-08-13T01:15:36+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "EODHD news request failed: ReadTimeout", "mapped_mentions": 3749, "unmapped_mentions": 1776}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 28.72, "latest_week": "2026-08-07", "one_week_move": -0.8, "four_week_move": 4.5, "twelve_week_move": 4.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.181498, "market_dynamics_buy_signal": false, "relative_strength": -6.744363, "fair_value_gap": 23.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.9372, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.8% over one week, +4.5% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": ["Sentiment confirms active trend"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": [], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 7}], "tiers": [{"label": "Direct company coverage", "count": 7}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 6}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "61/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "71/100", "tone": "positive", "text": "6.05 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "7", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "16/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.8% over one week, +4.5% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Nextensa delivers strong half-year results, supported by several successful transactions"}], "updated_at": "2026-08-13T01:47:07.235682+00:00", "detail_intelligence": {"headline": "Balanced read", "summary": "Constructive news tone is drawn from 7 fresh independent stories, including 7 company-specific items across 1 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 61, "display": "61", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 72, "display": "72", "tone": "positive", "note": "solid confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "7 direct stories"}, {"label": "Evidence agreement", "value": 84, "display": "84", "tone": "positive", "note": "16/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 76, "note": "6.05 effective stories"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 79, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 84, "note": "cross-story consistency"}, {"label": "Source independence", "value": 0, "note": "lower publisher concentration"}], "freshness": 79, "source_independence": 0, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 2, "score": 70, "tone": "positive", "x": 683.2, "y": 98.6, "volume_height": 34.7, "volume_y": 231.3}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 0, "score": null, "tone": "neutral", "x": 820.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 2, "score": 80, "tone": "positive", "x": 866.4, "y": 80.4, "volume_height": 34.7, "volume_y": 231.3}, {"date": "2026-08-12", "label": "12 Aug", "count": 3, "score": 57, "tone": "neutral", "x": 912.2, "y": 122.3, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "683.2,98.6 866.4,80.4 912.2,122.3", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Deteriorating", "tone": "negative", "recent_score": 66, "prior_score": 70, "delta": -4, "recent_count": 5, "prior_count": 2, "volume_delta": 3}, "freshness_buckets": [{"label": "Last 24 hours", "count": 3, "share": 43}, {"label": "1 to 3 days", "count": 2, "share": 29}, {"label": "4 to 7 days", "count": 2, "share": 29}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 7, "share": 100, "score": 66, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 6, "share": 86, "score": 68, "tone": "positive"}, {"label": "Regulatory and legal", "count": 1, "share": 14, "score": 59, "tone": "positive"}], "topics": [{"label": "Earnings", "count": 5, "share": 71}, {"label": "Revenue Growth", "count": 2, "share": 29}, {"label": "Guidance", "count": 2, "share": 29}, {"label": "Growth Rate", "count": 2, "share": 29}, {"label": "Fda Approval", "count": 2, "share": 29}, {"label": "Biotech", "count": 2, "share": 29}, {"label": "Balance Sheet", "count": 2, "share": 29}, {"label": "Transactions", "count": 1, "share": 14}, {"label": "Supply Chain", "count": 1, "share": 14}, {"label": "Revenue", "count": 1, "share": 14}], "supporting": [{"label": "Direct evidence", "text": "7 current stories are mapped specifically to NTGY."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 84/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Nextensa delivers strong half-year results, supported by several successful transactions", "summary": "Nextensa NV PRESS RELEASE Regulated information Brussels, 12 August 2026, 5:55PM HIGHLIGHTS Nextensadeliversstronghalf-yearresults,supportedbyseveralsuccessful transactions Nextensa achieved strong results in the first half of 2026. The period was marked by several successful transactions, including the sale of Gewerbepark Stadlau in Vienna, the forward sale of The Rock and the sale of B&B Hotels in Cloche d'Or. The granting of the planning and environmental permits for Lake Side in Brussels and the reservation by Vicinity of a substantial residential portion of Bel Towers further underline th", "url": "https://finance.yahoo.com/real-estate/articles/nextensa-delivers-strong-half-results-155500459.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:55:00+00:00", "published_display": "12 Aug 2026 15:55", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.239, "duplicate_count": 1, "topics": ["Balance Sheet", "Development", "Dividends", "Financials", "Real Estate", "Transactions"]}, "article_count": 7, "updated_at": "2026-08-13T00:43:16.928069+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 172.4, "label": "13 Feb 2026", "close": 25.54, "index": 100.0}, {"x": 77.5, "y": 188.8, "label": "20 Feb 2026", "close": 24.95, "index": 97.7}, {"x": 113.1, "y": 166.4, "label": "27 Feb 2026", "close": 25.75, "index": 100.8}, {"x": 148.6, "y": 204.2, "label": "06 Mar 2026", "close": 24.41, "index": 95.6}, {"x": 184.1, "y": 197.6, "label": "13 Mar 2026", "close": 24.64, "index": 96.5}, {"x": 219.6, "y": 174.0, "label": "20 Mar 2026", "close": 25.48, "index": 99.8}, {"x": 255.2, "y": 169.6, "label": "27 Mar 2026", "close": 25.64, "index": 100.4}, {"x": 290.7, "y": 145.5, "label": "03 Apr 2026", "close": 26.5, "index": 103.8}, {"x": 326.2, "y": 137.1, "label": "10 Apr 2026", "close": 26.8, "index": 104.9}, {"x": 361.7, "y": 139.9, "label": "17 Apr 2026", "close": 26.7, "index": 104.5}, {"x": 397.3, "y": 121.9, "label": "24 Apr 2026", "close": 27.34, "index": 107.0}, {"x": 432.8, "y": 137.6, "label": "01 May 2026", "close": 26.78, "index": 104.9}, {"x": 468.3, "y": 138.8, "label": "08 May 2026", "close": 26.74, "index": 104.7}, {"x": 503.8, "y": 119.7, "label": "15 May 2026", "close": 27.42, "index": 107.4}, {"x": 539.4, "y": 55.8, "label": "22 May 2026", "close": 29.7, "index": 116.3}, {"x": 574.9, "y": 88.3, "label": "29 May 2026", "close": 28.54, "index": 111.7}, {"x": 610.4, "y": 77.1, "label": "05 Jun 2026", "close": 28.94, "index": 113.3}, {"x": 645.9, "y": 63.1, "label": "12 Jun 2026", "close": 29.44, "index": 115.3}, {"x": 681.5, "y": 88.3, "label": "19 Jun 2026", "close": 28.54, "index": 111.7}, {"x": 717.0, "y": 121.3, "label": "26 Jun 2026", "close": 27.36, "index": 107.1}, {"x": 752.5, "y": 128.5, "label": "03 Jul 2026", "close": 27.11, "index": 106.1}, {"x": 788.0, "y": 118.0, "label": "10 Jul 2026", "close": 27.48, "index": 107.6}, {"x": 823.6, "y": 96.1, "label": "17 Jul 2026", "close": 28.26, "index": 110.7}, {"x": 859.1, "y": 63.1, "label": "24 Jul 2026", "close": 29.44, "index": 115.3}, {"x": 894.6, "y": 77.1, "label": "31 Jul 2026", "close": 28.94, "index": 113.3}, {"x": 930.1, "y": 83.3, "label": "07 Aug 2026", "close": 28.72, "index": 112.5}], "sentiment_points": [{"x": 685.5, "y": 126.3, "label": "19 Jun 2026", "score": 52}, {"x": 686.1, "y": 126.3, "label": "19 Jun 2026", "score": 52}, {"x": 690.5, "y": 126.3, "label": "20 Jun 2026", "score": 52}, {"x": 692.3, "y": 126.3, "label": "21 Jun 2026", "score": 52}, {"x": 694.6, "y": 126.3, "label": "21 Jun 2026", "score": 52}, {"x": 699.3, "y": 128.2, "label": "22 Jun 2026", "score": 51}, {"x": 699.9, "y": 128.2, "label": "22 Jun 2026", "score": 51}, {"x": 700.2, "y": 128.2, "label": "22 Jun 2026", "score": 51}, {"x": 719.8, "y": 131.8, "label": "26 Jun 2026", "score": 49}, {"x": 723.7, "y": 131.8, "label": "27 Jun 2026", "score": 49}, {"x": 726.4, "y": 130.0, "label": "27 Jun 2026", "score": 50}, {"x": 728.4, "y": 131.8, "label": "28 Jun 2026", "score": 49}, {"x": 733.3, "y": 130.0, "label": "29 Jun 2026", "score": 50}, {"x": 739.5, "y": 128.2, "label": "30 Jun 2026", "score": 51}, {"x": 746.2, "y": 128.2, "label": "01 Jul 2026", "score": 51}, {"x": 755.9, "y": 128.2, "label": "03 Jul 2026", "score": 51}, {"x": 756.5, "y": 130.0, "label": "03 Jul 2026", "score": 50}, {"x": 757.8, "y": 128.2, "label": "04 Jul 2026", "score": 51}, {"x": 766.9, "y": 126.3, "label": "05 Jul 2026", "score": 52}, {"x": 774.2, "y": 126.3, "label": "07 Jul 2026", "score": 52}, {"x": 775.4, "y": 126.3, "label": "07 Jul 2026", "score": 52}, {"x": 775.5, "y": 126.3, "label": "07 Jul 2026", "score": 52}, {"x": 787.6, "y": 126.3, "label": "09 Jul 2026", "score": 52}, {"x": 789.4, "y": 126.3, "label": "10 Jul 2026", "score": 52}, {"x": 796.5, "y": 126.3, "label": "11 Jul 2026", "score": 52}, {"x": 800.1, "y": 126.3, "label": "12 Jul 2026", "score": 52}, {"x": 805.2, "y": 126.3, "label": "13 Jul 2026", "score": 52}, {"x": 824.8, "y": 126.3, "label": "17 Jul 2026", "score": 52}, {"x": 831.9, "y": 126.3, "label": "18 Jul 2026", "score": 52}, {"x": 833.0, "y": 126.3, "label": "18 Jul 2026", "score": 52}, {"x": 841.3, "y": 126.3, "label": "20 Jul 2026", "score": 52}, {"x": 846.3, "y": 126.3, "label": "21 Jul 2026", "score": 52}, {"x": 854.9, "y": 126.3, "label": "23 Jul 2026", "score": 52}, {"x": 856.7, "y": 126.3, "label": "23 Jul 2026", "score": 52}, {"x": 857.6, "y": 126.3, "label": "23 Jul 2026", "score": 52}, {"x": 860.0, "y": 126.3, "label": "24 Jul 2026", "score": 52}, {"x": 861.8, "y": 126.3, "label": "24 Jul 2026", "score": 52}, {"x": 864.3, "y": 126.3, "label": "25 Jul 2026", "score": 52}, {"x": 865.7, "y": 126.3, "label": "25 Jul 2026", "score": 52}, {"x": 877.2, "y": 124.5, "label": "27 Jul 2026", "score": 53}, {"x": 888.2, "y": 124.5, "label": "29 Jul 2026", "score": 53}, {"x": 891.8, "y": 126.3, "label": "30 Jul 2026", "score": 52}, {"x": 895.7, "y": 126.3, "label": "31 Jul 2026", "score": 52}, {"x": 958.0, "y": 98.7, "label": "12 Aug 2026", "score": 67}], "price_path": "42.0,172.4 77.5,188.8 113.1,166.4 148.6,204.2 184.1,197.6 219.6,174.0 255.2,169.6 290.7,145.5 326.2,137.1 361.7,139.9 397.3,121.9 432.8,137.6 468.3,138.8 503.8,119.7 539.4,55.8 574.9,88.3 610.4,77.1 645.9,63.1 681.5,88.3 717.0,121.3 752.5,128.5 788.0,118.0 823.6,96.1 859.1,63.1 894.6,77.1 930.1,83.3", "sentiment_path": "685.5,126.3 686.1,126.3 690.5,126.3 692.3,126.3 694.6,126.3 699.3,128.2 699.9,128.2 700.2,128.2 719.8,131.8 723.7,131.8 726.4,130.0 728.4,131.8 733.3,130.0 739.5,128.2 746.2,128.2 755.9,128.2 756.5,130.0 757.8,128.2 766.9,126.3 774.2,126.3 775.4,126.3 775.5,126.3 787.6,126.3 789.4,126.3 796.5,126.3 800.1,126.3 805.2,126.3 824.8,126.3 831.9,126.3 833.0,126.3 841.3,126.3 846.3,126.3 854.9,126.3 856.7,126.3 857.6,126.3 860.0,126.3 861.8,126.3 864.3,126.3 865.7,126.3 877.2,124.5 888.2,124.5 891.8,126.3 895.7,126.3 958.0,98.7", "price_change": 12.5, "sentiment_change": 15, "latest_close": 28.72, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}